
SentiSense
Ctrl+K
Quick tip: Press
to search stocks
M
MRK
Merck & Co., Inc.
$115.61
-0.30 (-0.26%)
Summary
Stories
News
Metrics
Fundamentals
Holders
Full institutional holders data is a Pro feature
UpgradeInstitutional Holders
3199
tracked filers
Total Institutional Value
$73.7B
3199 holders tracked
Report Date
Q4 2025
SEC 13F-HR filing
Notable changes (1)
| Holder | Category | Shares | Value | Weight | Change |
|---|---|---|---|---|---|
STATE STREET CORP | Index Fund | 118.2M | $10.0B | -- | -0.3% |
WELLINGTON MANAGEMENT GROUP LLP | Other | 70.9M | $6.0B | -- | -2.9% |
GEODE CAPITAL MANAGEMENT, LLC | Index Fund | 52.6M | $4.4B | -- | +1.2% |
DLD Asset Management, LP | Other | 47.5M | $47.1M | -- | +30.1% |
NORGES BANK | Sovereign Wealth | 33.8M | $3.8B | -- | -6.5% |
Data source: SEC EDGAR 13F-HR filings
Company Profile
Symbol
MRK
Market Cap
$286.57B
IPO Date
Apr 20, 1949
CEO
Robert M. Davis
Employees
75,000
Sector
--
Industry
PHARMACEUTICAL PREPARATIONS
Country
United States
Exchange
--
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Read MoreSimilar Stocks
PFE
Pfizer Inc.
$26.58
-1.04%
ABT
Abbott Laboratories
$108.03
-0.10%
BMY
Bristol Myers Squibb Company
$59.08
+0.22%